🔗 Share this article

As the United States proceeds with sweeping revisions to its vaccination schedules, a particular individual appears somewhat surprisingly: Dr. Tracy Beth Høeg, a US-based physician and public health researcher who rose to prominence by casting doubt on coronavirus vaccinations during the global health crisis and has zeroed in on possible deaths following COVID-19 immunization in her recent tenure at the FDA.

Proposed Shifts to Childhood Vaccine Schedule

Public health authorities planned to announce major changes to the childhood immunization program in December, synchronizing the US with Denmark’s vaccine program, sources say – a substantial departure that would place the US out of step with many the world with insufficient data for improved outcomes. The planned update has been pushed back until the coming year.

Instead of the director of the vaccine center, Dr. Høeg is scheduled to address the audience at the gathering. She was just designated interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to lead the center this calendar year.

A Shift at the Agency

The acting appointment might represent a closer partnership between the drug and vaccine branches as Høeg and Prasad consolidate power at the regulatory agency – and it signals a increased emphasis upon rolling back previously authorized immunizations at the FDA.

Høeg has often pushed for discontinuing some pediatric shot schedules in the US in order to be more similar to the Danish model, a country with universal health coverage and a population about the size of Wisconsin’s.

In her initial statements, she has continued to focus on vaccination policy – typically the purview of Prasad, director of the FDA’s CBER – instead of drug regulation.

Doubts Over Qualifications

Dr. Høeg has little discernible background in medication creation, approval processes or leadership, which has been standard for former heads of the biologics center. She has worked at the FDA as a senior adviser to the FDA chief and CBER since March.

“She appears not to have the necessary background” for leading the drug-regulation department, said Dr. Jonathan Howard. “She’s never run a clinical trial. She has no expertise in managing a sizeable institution. She has no expertise in pharmaceutical oversight.”

Previous heads of CBER would “understand legal statutes and the underlying principles of drug development”, said a former acting FDA commissioner. “Objectively, she doesn’t have the type of experience that prior appointees who ran the center have had.”

This division has an enormous range of responsibilities at the FDA, she pointed out.

“Many people just pays attention on the new drug program, but the generic drug division approves numerous off-brand pharmaceuticals. There is also a biologic copycat branch, non-prescription drug unit and so forth, and every single one need to be managed,” she noted. “The area you don’t keep your eye on, that is precisely what that I always told people is going to bite you.”

There is also, a major management element to the position, which manages in excess of 5,000 staff members. “It’s a massive administrative position, if you execute it properly,” the former official concluded.

Response and Contentious Policies

Regarding questions about Dr. Høeg's credentials and whether this appointment signifies increased cooperation among agency officials on vaccines, a representative responded that the “concerns rely on flawed premises”.

“Her experience aligns with the functions of her role,” the official said, noting the period Dr. Høeg spent advising the agency head on “pharmaceutical safety and oversight research, including computational safety modeling and vaccine surveillance”.

In her interim role, Dr. Høeg inherits the commissioner’s recently launched expedited review system, a controversial one-day medication authorization process that allegedly worried her former heads. “How are these therapies being selected for this fast-track system? Who makes the choices?” Howard asked. “There is a lot of secrecy going on at the FDA right now.”

In general, he stated, “the Food and Drug Administration seems to be moving towards less stringent oversight of all drugs, aside from immunizations.”

Documented History on Vaccines

Concerning vaccines, Høeg has a more established, if troubling, history, some experts said. She published a research paper using unverified crowd-sourced reports to determine the frequency of myocarditis after COVID-19 vaccination. She consulted for the Florida chief medical officer Dr. Joseph Ladapo, who was said to have modified findings to imply COVID-19 vaccines are more dangerous than they are.

Part of her “policy goals” for the new government featured revising guidelines for novel immunizations and halting “optional” immunizations, she remarked after the election on a audio program. At the FDA, Dr. Høeg has reportedly suggested barring young men from obtaining Covid vaccines.

“She’s an all-around ideologue who starts off with her conclusions and tailors the evidence to accommodate the evidence in a very deceptive, dishonest fashion,” Dr. Howard argued.

Consolidating Power and a “Campaign of Retribution”

Dr. Høeg aligned with other contrarians, {like|